Nanotechnology is being used to improve the diagnosis and treatment of breast cancer, according to an April 10 review. The review outlines how nanomaterials and nanoparticles are applied in breast cancer therapy, offering new options compared to conventional treatments.
Breast cancer is one of the most common cancers among women worldwide, with high rates of illness and death. The article highlights that traditional therapies often face challenges such as lack of target specificity, drug resistance, and side effects. Nanomedicine aims to address these issues by enabling more precise delivery of drugs directly to tumor cells.
The review explains that nanomaterials have unique properties due to their small size—between 1 and 100 nanometers—which increases their solubility and interaction with biological systems. This allows for improved pharmacokinetics, targeted delivery, better absorption by tumors, and reduced doses required for effective treatment.
Different types of nanocarriers are discussed in the review. Lipid nanoparticles, nanoemulsions, polymeric nanoparticles, and metal-based nanoparticles can all be used as drug carriers. These carriers enhance stability and control release rates while reducing toxicity. For example, chitosan-based nanocarriers help drugs enter cancer cells more efficiently through electrostatic interactions.
Clinical studies mentioned in the article show that using nanoparticle-based formulations leads to better outcomes in animal models when compared with traditional approaches. Photothermal therapy using nanomaterials has shown promise for treating metastatic breast cancer while minimizing harm to healthy tissue.
While there are clear advantages—including targeted delivery and improved effectiveness—the review also notes gaps in knowledge about the safety of these materials inside the body. It calls for further research into toxicity before these technologies can be widely adopted in clinical settings.
